Medigen Vaccine Biologics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	592.04	715.61	1,393	1,204	1,380
Short-Term Investments	1,180	1,200	2,364	2,980	800
Trading Asset Securities	-	-	-	52.99	53.1
Cash & Short-Term Investments	1,772	1,916	3,757	4,237	2,233
Cash Growth	-7.50%	-49.02%	-11.33%	89.77%	28.87%
Accounts Receivable	130.02	118.03	149.11	194.4	640.19
Other Receivables	12.52	9.98	49.74	1.17	0.07
Receivables	142.54	128.01	198.84	195.57	640.26
Inventory	393.75	452.06	383.64	903.4	610.84
Prepaid Expenses	16.56	20.44	13.49	12.37	32.29
Other Current Assets	37.87	40.79	48.14	113.89	205.07
Total Current Assets	2,363	2,557	4,401	5,462	3,721
Property, Plant & Equipment	1,244	1,354	1,385	1,470	1,414
Long-Term Investments	287.97	407.99	246.13	263.56	54
Other Intangible Assets	21.14	29.38	38.3	45.36	52.98
Other Long-Term Assets	17.93	16.07	22.36	106.83	57.26
Total Assets	3,934	4,364	6,093	7,348	5,299
Accounts Payable	10.6	13.39	25.89	109.1	88.53
Current Portion of Long-Term Debt	-	23.15	1,708	-	-
Current Portion of Leases	13.84	16.11	12	11.78	1.99
Current Unearned Revenue	-	-	-	-	111.41
Other Current Liabilities	160.61	161.57	245.73	234.35	237.15
Total Current Liabilities	185.05	214.22	1,992	355.23	439.09
Long-Term Debt	-	-	-	1,678	-
Long-Term Leases	269.6	299.7	254.36	266.35	183.87
Other Long-Term Liabilities	-	-	-	19.25	-
Total Liabilities	454.64	513.92	2,246	2,319	622.95
Common Stock	3,287	3,287	3,286	3,278	2,129
Additional Paid-In Capital	357.92	407.38	1,551	2,798	1,135
Retained Earnings	-140.23	61.02	-1,018	-1,132	1,410
Comprehensive Income & Other	-25.92	94.25	27.85	84.03	1.92
Shareholders' Equity	3,479	3,850	3,847	5,029	4,676
Total Liabilities & Equity	3,934	4,364	6,093	7,348	5,299
Total Debt	283.44	338.96	1,974	1,956	185.85
Net Cash (Debt)	1,489	1,577	1,783	2,281	2,047
Net Cash Growth	-5.58%	-11.56%	-21.85%	11.45%	32.50%
Net Cash Per Share	4.54	4.80	5.43	7.05	6.37
Filing Date Shares Outstanding	324.06	328.73	328.61	327.84	315.67
Total Common Shares Outstanding	324.06	328.73	328.61	327.84	315.67
Working Capital	2,178	2,343	2,410	5,107	3,282
Book Value Per Share	10.74	11.71	11.71	15.34	14.81
Tangible Book Value	3,458	3,821	3,808	4,984	4,623
Tangible Book Value Per Share	10.67	11.62	11.59	15.20	14.65
Buildings	-	1,133	1,130	1,127	1,121
Machinery	-	686.4	650.64	626.59	570.9
Construction In Progress	-	2.57	21.37	14.54	4.7
Leasehold Improvements	-	9.35	3.34	3.03	2.55

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.